Apollomics vs BeyondSpring
APLM and BYSI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and BYSI compare
BeyondSpring scores higher on the StockData Score (4 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | BYSI |
|---|---|---|
| Size and price | ||
| Share price | $18.60 | $0.644 |
| Change, 1 year | 27.1% | −66.6% |
| Change, 5 years | – | −95.1% |
| Beta (5Y) | 0.69 | 0.54 |
| Employees | 14 | 44 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Financial health | ||
| Current ratio | 0.96 (better) | 0.70 |
| Piotroski F-score | – | 2 |
| Ownership | ||
| Held by institutions | – | 14.7% |
| Held by insiders | 76.0% | 31.2% |
| Insider net buying, 12 months | $8.3M (better) | $0 |
| Short interest, % of float | – | 8.0% |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- BYSI stock overview
- BYSI income statement
- BYSI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.